ScripBoth private and public biopharmaceutical companies are struggling to raise fresh capital for ongoing research and development programs, despite expectations earlier in 2025 that financial market con
ScripNovo Nordisk’s Wegovy (injectable semaglutide) has made its India debut, setting the stage for a tight battle with rival Eli Lilly’s Mounjaro (tirzepatide) in a market where an estimated 254 million p
ScripAmgen’s updated Phase II data for MariTide in obesity may not have been the results the firm was looking for, but Amgen is trying to assure investors that based on learnings from an ongoing Phase II t
ScripEli Lilly has presented data which reinforces the view that its once daily pill, the GLP-1 agonist candidate orforglipron, is a future global market leader in obesity treatment. Topline efficacy data